Alnylam Pharmaceuticals, Inc. Stock Analysis & AI Score
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Alnylam Pharmaceuticals, Inc. (ALNY) holds an ST Score of 60.4 out of 100 (B), with its strongest factor being Profitability (A+) and its weakest Valuation (F). Analysts rate ALNY Buy across 52 ratings with a $347.33 average price target (+0.4% vs the current $244.32).
- Strongest
- ProfitabilityA+
- Weakest
- ValuationF
All factor grades
- ProfitabilityA+
- GrowthA+
- SentimentA+
- ForecastA-
- MomentumC-
- Financial StrengthD
- ValuationF
- Piotroski6/9
Contact
ALNY stock: frequently asked questions
What is ALNY's ST Score?
Alnylam Pharmaceuticals, Inc. (ALNY) has an ST Score of 60.4 out of 100, an overall grade of B. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is ALNY a buy, sell, or hold?
Wall Street's consensus rating on ALNY is Buy based on 52 analyst ratings. Our own ST Score grades it B (60.4/100). This is data, not investment advice — always do your own research.
What is ALNY's valuation grade?
Alnylam Pharmaceuticals, Inc. (ALNY) earns a valuation grade of F, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is ALNY's growth grade?
Alnylam Pharmaceuticals, Inc. (ALNY) earns a growth grade of A+, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is ALNY's profitability grade?
Alnylam Pharmaceuticals, Inc. (ALNY) earns a profitability grade of A+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is ALNY's financial strength grade?
Alnylam Pharmaceuticals, Inc. (ALNY) earns a financial strength grade of D, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for ALNY?
The average analyst price target for Alnylam Pharmaceuticals, Inc. (ALNY) is $347.33 from 52 analysts, which is +0.4% versus the recent price of $244.32.
What is ALNY's Piotroski score?
Alnylam Pharmaceuticals, Inc. (ALNY) has a Piotroski F-Score of 6 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.